Market Spotlight on Huntington's Disease 2017-2021 & 2025

Dublin, Jan. 16, 2018 -- The "Market Spotlight: Huntington's Disease" report has been added to ResearchAndMarkets.com's offering.

This Market Spotlight report covers the Huntington's disease market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

• The author estimates that in 2016 there were 155,620 prevalent cases of Huntington's disease in adults aged 30 years and older worldwide, and forecasts that number to increase to 181,760 prevalent cases by 2025.
• Northern America is estimated to have the largest prevalence proportion (0.0073%) while Asia has the smallest prevalence proportion (0.0004%).
• A majority of industry-sponsored drugs in active clinical development for Huntington's disease are in Phase II. Therapies in mid and late-stage development for Huntington's disease focus on a wide variety of targets. Among these therapies, Procysbi, an enteric-coated micro-bead formulation of cysteamine bitartrate, is closest to market. The majority of the pipeline drugs in mid-to-late-stage development for Huntington's disease are administered via the oral route.
• Valeant Pharmaceuticals' Xenazine and Teva Pharmaceutical's Austedo, which target vesicular monamine transporters, are the only marketed drugs for Huntington's disease. The drugs are administered via the oral route. Austedo, a deuterium-substituted analogue of tetrabenazine, was approved by the US Food and Drug Administration (FDA) in April 2017.
• The topline Phase II trial results for IONIS-HTTRx and Nerventra are the only high-impact upcoming events in the Huntington's disease space.
• There were nine licensing and asset acquisition activities involving Huntington's disease drugs during 2012-17, three of which occurred in 2015. The exclusive licensing agreement in 2015 between Neurocrine Biosciences and Mitsubishi Tanabe Pharma to develop and commercialize Neurocrine Biosciences' VMAT2 inhibitor - NBI-98854 - in Japan and certain selected Asian markets, for $115m, was the largest deal during the 2012-17 period.
• Xenazine's sales have ranked highest in the Huntington's disease space during 2012-16. However, during 2017-22, Austedo's sales are forecasted to grow, peaking at $983m in 2022.
• The clinical trials distribution across Phase I-IV indicates that the majority of the drugs are in Phase I-II, and only 19% of trials are in Phase III-IV.
• Clinical trial activity in the Huntington's disease space is dominated by completed trials. Pfizer and Medivation have the highest number of completed clinical trials for Huntington's disease.
• While non-industry sponsors include Huntington Study Group, National Institute of Neurological Disorders and Stroke, and Massachusetts General Hospital, Pfizer and Medivation are the biggest industry sponsors of trials in Huntington's disease

Key Topics Covered:

1 KEY TAKEAWAYS

2 DISEASE BACKGROUND

• Huntington's disease subtypes

3 TREATMENT

• Treatment of chorea
• Treatment of parkinsonism
• Treatment of behavioral and psychiatric dysfunction

4 EPIDEMIOLOGY

5 PIPELINE DRUGS

6 MARKETED DRUGS

• Approvals by country

7 KEY UPCOMING EVENTS

8 KEY REGULATORY EVENTS

• FDA Approved Austedo

9 LICENSING AND ASSET ACQUISITION DEALS

10 PARENT PATENTS

11 REVENUE OPPORTUNITY

12 CLINICAL TRIAL LANDSCAPE

• Sponsors by status
• Sponsors by phase

13 BIBLIOGRAPHY

• Prescription information

14 APPENDIX

For more information about this report visit https://www.researchandmarkets.com/research/b8pjc3/market_spotlight?w=12

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Central Nervous System Drugs